Results of Adjuvant FOLFOX Regimens in Stage III Colorectal Cancer Patients: Retrospective Analysis of 667 Patients

Basit Öğe Kaydı
dc.contributor.authorUncu, Dogan
dc.contributor.authorAksoy, Sercan
dc.contributor.authorCetin, Bulent
dc.contributor.authorYetisyigit, Tarkan
dc.contributor.authorOzdemir, Nuriye
dc.contributor.authorBerk, Veli
dc.contributor.authorDane, Faysal
dc.date.accessioned2024-04-24T17:14:28Z
dc.date.available2024-04-24T17:14:28Z
dc.date.issued2013
dc.departmentDicle Üniversitesien_US
dc.description.abstractObjective: The aim of this study was to assess the use of 5-fluorouracil (5-FU), leucovorin and oxaliplatin (FOLFOX) regimens in clinical practice according to their efficacy and toxicity. Methods: Patients who received oxaliplatin-containing regimens after curative resection for colorectal carcinoma from 10 different oncology centers between May 2004 and December 2009 were included in the study. All patients were treated with FOLFOX regimens. Patients with rectal carcinoma were also treated with chemoradiotherapy with 5-FU after 2 cycles of a FOLFOX regimen. Results: The median age of the patients was 56 years (range 17-78). Of the total 667 patients, 326 were given FOLFOX-4, 232 were given modified FOLFOX-4 and 109 were given FOLFOX-6. The distribution according to disease stage was 33 patients with stage IIIA colorectal cancer, 382 patients with stage IIIB and 252 patients with stage IIIC. The most common adverse events were neutropenia (54%), nausea (36.9%), neuropathy (38.2%) and anemia (33.1%) for all grades. The median follow-up time was 23 months (range 1-79). Three-year disease-free survival and overall survival were 65 and 85.7%, respectively. Conclusion: The different oxaliplatin-containing 5-FU-based adjuvant chemotherapy regimens in patients with stage III colorectal cancer seemed to be at least equal in terms of efficacy regardless of the method of 5-FU administration or oxaliplatin dose. Copyright (C) 2012 S. Karger AG, Baselen_US
dc.identifier.doi10.1159/000336902
dc.identifier.endpage245en_US
dc.identifier.issn0030-2414
dc.identifier.issue4en_US
dc.identifier.pmid23392240
dc.identifier.scopus2-s2.0-84873332227
dc.identifier.scopusqualityQ2
dc.identifier.startpage240en_US
dc.identifier.urihttps://doi.org/10.1159/000336902
dc.identifier.urihttps://hdl.handle.net/11468/17966
dc.identifier.volume84en_US
dc.identifier.wosWOS:000315030800008
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherKargeren_US
dc.relation.ispartofOncology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectColorectal Adenocarcinomaen_US
dc.subjectAdjuvanten_US
dc.subjectOxaliplatinen_US
dc.titleResults of Adjuvant FOLFOX Regimens in Stage III Colorectal Cancer Patients: Retrospective Analysis of 667 Patientsen_US
dc.titleResults of Adjuvant FOLFOX Regimens in Stage III Colorectal Cancer Patients: Retrospective Analysis of 667 Patients
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu